Menu Search
Equities

Clene Inc.

CLNN:NAQ

Clene Inc.

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.69
  • Today's Change-0.20 / -3.40%
  • Shares traded95.50k
  • 1 Year change-31.61%
  • Beta0.3893
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Clene Inc. had net income fall 65.47% from a loss of 29.92m to a larger loss of 49.50m despite a 38.27% increase in revenues from 473.00k to 654.00k. An increase in the cost of goods sold as a percentage of sales from 5.50% to 18.50% was a component in the falling net income despite rising revenues.
Gross margin81.00%
Net profit margin-6,890.50%
Operating margin-8,166.29%
Return on assets-56.31%
Return on equity-289.66%
Return on investment-81.90%
More ▼

Cash flow in USDView more

In 2023, Clene Inc. increased its cash reserves by 57.04%, or 10.49m. Cash Flow from Financing totalled 42.16m or 6,446.94% of revenues. In addition the company used 30.17m for operations while cash used for investing totalled 1.50m.
Cash flow per share-4.48
Price/Cash flow per share--
Book value per share-0.0783
Tangible book value per share-0.0783
More ▼

Balance sheet in USDView more

Clene Inc. has a Debt to Total Capital ratio of 101.87%, a lower figure than the previous year's 120.00%.
Current ratio0.9943
Quick ratio0.993
Total debt/total equity--
Total debt/total capital1.02
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.